• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

Prdm12 调控一个表观遗传检查点,该检查点将神经免疫相互作用与 CD8 T 细胞耗竭抑制的抗肿瘤免疫联系起来。

Prdm12 governs an epigenetic checkpoint linking neuroimmune cross-talk to CD8 T cell exhaustion-suppressed antitumor immunity.

作者信息

Liu Guolong, Tian Xiaoling, Wang Qiudao, Xu Saijuan, Jiang Yanhong, Gao Ying, Wu Yuxuan

机构信息

Shanghai Frontiers Science Center of Genome Editing and Cell Therapy, Shanghai Key Laboratory of Regulatory Biology, Institute of Biomedical Sciences and School of Life Sciences, East China Normal University, Shanghai 200241, China.

YolTech Therapeutics, Shanghai 201199, China.

出版信息

Sci Adv. 2025 Aug 15;11(33):eadx9221. doi: 10.1126/sciadv.adx9221.

DOI:10.1126/sciadv.adx9221
PMID:40815657
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC12356268/
Abstract

CD8 T play essential roles in antitumor immune responses. However, immunotherapy has limited clinical efficacy in many solid tumors. Here, we performed an epigenetic-wide CRISPR-Cas9 screen in CD8 T cells directly under cancer immunotherapy setting and found that is a transcriptional repressor implicated in nociceptive neuron development but uncharacterized within immunological contexts. deletion markedly enhanced in vivo tumor clearance of mouse CD8 T cells and promoted activation, effector differentiation marker expression, and cytokine secretion in both murine and human CD8 T cells in vitro. Mechanistically, deficiency augmented effector transcriptional programs while inhibiting exhaustion of CGRP-RAMP1 neuroimmune axis facilitation. Additionally, ablation remodeled the chromatin accessibility landscape, with H3K9me3 deposition at loci regulating T cell differentiation ( and ) and exhaustion ( and ). These results together reveal a negative regulatory mechanism for CD8 T cells and advance our understanding of cancer immunotherapy by linking neurobiological signaling to immune regulation.

摘要

CD8 T细胞在抗肿瘤免疫反应中发挥着重要作用。然而,免疫疗法在许多实体瘤中的临床疗效有限。在此,我们在癌症免疫治疗环境下直接对CD8 T细胞进行了全表观基因组CRISPR-Cas9筛选,发现[此处原文缺失具体基因名称]是一种转录抑制因子,与伤害性神经元发育有关,但在免疫背景下尚未得到充分研究。[此处原文缺失具体基因名称]的缺失显著增强了小鼠CD8 T细胞在体内的肿瘤清除能力,并在体外促进了小鼠和人类CD8 T细胞的激活、效应分化标志物表达和细胞因子分泌。从机制上讲,[此处原文缺失具体基因名称]缺陷增强了效应转录程序,同时抑制了降钙素基因相关肽-受体活性修饰蛋白1(CGRP-RAMP1)神经免疫轴促进的耗竭。此外,[此处原文缺失具体基因名称]的缺失重塑了染色质可及性景观,在调节T细胞分化([此处原文缺失具体基因名称]和[此处原文缺失具体基因名称])和耗竭([此处原文缺失具体基因名称]和[此处原文缺失具体基因名称])的基因座上有H3K9me3沉积。这些结果共同揭示了CD8 T细胞的一种负调控机制,并通过将神经生物学信号与免疫调节联系起来,推进了我们对癌症免疫治疗的理解。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/d9fc/12356268/39b96503ec00/sciadv.adx9221-f8.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/d9fc/12356268/06f2a0714efe/sciadv.adx9221-f1.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/d9fc/12356268/ed3824063cb7/sciadv.adx9221-f2.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/d9fc/12356268/a316ac63c7aa/sciadv.adx9221-f3.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/d9fc/12356268/08fc1d0c8bdb/sciadv.adx9221-f4.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/d9fc/12356268/1768709f8a01/sciadv.adx9221-f5.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/d9fc/12356268/247854d65ee4/sciadv.adx9221-f6.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/d9fc/12356268/e0dc64a308c7/sciadv.adx9221-f7.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/d9fc/12356268/39b96503ec00/sciadv.adx9221-f8.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/d9fc/12356268/06f2a0714efe/sciadv.adx9221-f1.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/d9fc/12356268/ed3824063cb7/sciadv.adx9221-f2.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/d9fc/12356268/a316ac63c7aa/sciadv.adx9221-f3.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/d9fc/12356268/08fc1d0c8bdb/sciadv.adx9221-f4.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/d9fc/12356268/1768709f8a01/sciadv.adx9221-f5.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/d9fc/12356268/247854d65ee4/sciadv.adx9221-f6.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/d9fc/12356268/e0dc64a308c7/sciadv.adx9221-f7.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/d9fc/12356268/39b96503ec00/sciadv.adx9221-f8.jpg

相似文献

1
Prdm12 governs an epigenetic checkpoint linking neuroimmune cross-talk to CD8 T cell exhaustion-suppressed antitumor immunity.Prdm12 调控一个表观遗传检查点,该检查点将神经免疫相互作用与 CD8 T 细胞耗竭抑制的抗肿瘤免疫联系起来。
Sci Adv. 2025 Aug 15;11(33):eadx9221. doi: 10.1126/sciadv.adx9221.
2
The mechanisms and clinical significance of CD8 T cell exhaustion in anti-tumor immunity.CD8 T细胞耗竭在抗肿瘤免疫中的机制及临床意义。
Cancer Biol Med. 2025 Jun 10;22(5). doi: 10.20892/j.issn.2095-3941.2024.0628.
3
STS2 deficiency revives CD8T cells from exhaustion and augments checkpoint blockade efficacy in cancer immunotherapy.STS2缺陷可使耗竭的CD8 T细胞恢复活力,并增强癌症免疫治疗中检查点阻断的疗效。
J Immunother Cancer. 2025 Jun 22;13(6):e010735. doi: 10.1136/jitc-2024-010735.
4
Loss of SGK1 supports metastatic colonization in hepatocellular carcinoma by promoting resistance to T cell-mediated immunity.SGK1缺失通过增强对T细胞介导免疫的抗性,促进肝细胞癌的转移定植。
J Hepatol. 2025 Jan 30. doi: 10.1016/j.jhep.2025.01.027.
5
MIAT promotes tumor-infiltrating CD8 T-cell exhaustion and malignant progression of renal cell carcinoma via activating JAK3/STAT3 pathway.MIAT通过激活JAK3/STAT3信号通路促进肾细胞癌肿瘤浸润性CD8 T细胞耗竭和恶性进展。
J Immunother Cancer. 2025 Jul 31;13(7):e011162. doi: 10.1136/jitc-2024-011162.
6
CXCL12/CXCR4 axis governs Treg spatial dominance over CD8+ T cells via IL-2 sequestration: a dual therapeutic target in prostate cancer.CXCL12/CXCR4轴通过隔离白细胞介素-2控制调节性T细胞对CD8 + T细胞的空间优势:前列腺癌的双重治疗靶点
Front Immunol. 2025 Jul 8;16:1626708. doi: 10.3389/fimmu.2025.1626708. eCollection 2025.
7
Targeting BATF2-RGS2 axis reduces T-cell exhaustion and restores anti-tumor immunity.靶向BATF2-RGS2轴可减轻T细胞耗竭并恢复抗肿瘤免疫力。
Mol Cancer. 2025 May 30;24(1):157. doi: 10.1186/s12943-025-02351-5.
8
Ex vivo pre-activation shifts the in vivo differentiation of adoptively transferred CD8 T cells in a melanoma model.在黑色素瘤模型中,体外预激活改变了过继转移的CD8 T细胞的体内分化。
Mol Immunol. 2025 Jun;182:139-149. doi: 10.1016/j.molimm.2025.04.007. Epub 2025 Apr 23.
9
CD24a knockout results in an enhanced macrophage- and CD8⁺ T cell-mediated anti-tumor immune responses in tumor microenvironment in a murine triple-negative breast cancer model.在小鼠三阴性乳腺癌模型中,CD24a基因敲除导致肿瘤微环境中巨噬细胞和CD8⁺ T细胞介导的抗肿瘤免疫反应增强。
J Biomed Sci. 2025 Aug 9;32(1):73. doi: 10.1186/s12929-025-01165-3.
10
[CD8+ T Cells in Anti-Tumor Immune Response].[抗肿瘤免疫反应中的CD8+ T细胞]
Gan To Kagaku Ryoho. 2025 Jul;52(7):485-491.

本文引用的文献

1
Targeting immunosenescence for improved tumor immunotherapy.针对免疫衰老以改善肿瘤免疫治疗。
MedComm (2020). 2024 Oct 28;5(11):e777. doi: 10.1002/mco2.777. eCollection 2024 Nov.
2
JunB is required for CD8+ T cell responses to acute infections.JunB是CD8 + T细胞对急性感染作出反应所必需的。
Int Immunol. 2025 Mar 6;37(4):203-220. doi: 10.1093/intimm/dxae063.
3
Neuropeptide signalling orchestrates T cell differentiation.神经肽信号调控 T 细胞分化。
Nature. 2024 Nov;635(8038):444-452. doi: 10.1038/s41586-024-08049-w. Epub 2024 Oct 16.
4
Epigenetic regulators of clonal hematopoiesis control CD8 T cell stemness during immunotherapy.表观遗传调控克隆性造血控制免疫治疗期间 CD8 T 细胞干性。
Science. 2024 Oct 11;386(6718):eadl4492. doi: 10.1126/science.adl4492.
5
Regional and intratumoral adoptive T-cell therapy.区域和肿瘤内过继性T细胞疗法。
Immunooncol Technol. 2024 Jun 12;24:100715. doi: 10.1016/j.iotech.2024.100715. eCollection 2024 Dec.
6
T cell dysfunction and therapeutic intervention in cancer.T 细胞功能障碍与癌症的治疗干预。
Nat Immunol. 2024 Aug;25(8):1344-1354. doi: 10.1038/s41590-024-01896-9. Epub 2024 Jul 18.
7
Innervation of nociceptor neurons in the spleen promotes germinal center responses and humoral immunity.脾脏中伤害感受器神经元的神经支配促进生发中心反应和体液免疫。
Cell. 2024 Jun 6;187(12):2935-2951.e19. doi: 10.1016/j.cell.2024.04.027. Epub 2024 May 20.
8
NR4a1/2 deletion promotes accumulation of TCF1 stem-like precursors of exhausted CD8 T cells in the tumor microenvironment.NR4a1/2 缺失促进肿瘤微环境中耗尽的 CD8 T 细胞中 TCF1 干细胞样前体的积累。
Cell Rep. 2024 Mar 26;43(3):113898. doi: 10.1016/j.celrep.2024.113898. Epub 2024 Mar 6.
9
Adoptive cell therapy for solid tumors beyond CAR-T: Current challenges and emerging therapeutic advances.过继细胞疗法治疗实体瘤:当前的挑战与新兴治疗进展。
J Control Release. 2024 Apr;368:372-396. doi: 10.1016/j.jconrel.2024.02.033. Epub 2024 Mar 6.
10
Epigenetic reprogramming of T cells: unlocking new avenues for cancer immunotherapy.T 细胞的表观遗传重编程:为癌症免疫治疗开辟新途径。
Cancer Metastasis Rev. 2024 Mar;43(1):175-195. doi: 10.1007/s10555-024-10167-w. Epub 2024 Jan 18.